NASDAQ:SLDB Solid Biosciences Q3 2026 Earnings Report $6.96 -0.10 (-1.47%) As of 11:13 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Solid Biosciences EPS ResultsActual EPSN/AConsensus EPS -$0.37Beat/MissN/AOne Year Ago EPSN/ASolid Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASolid Biosciences Announcement DetailsQuarterQ3 2026Date11/2/2026TimeBefore Market OpensConference Call DateFriday, November 6, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Solid Biosciences Earnings HeadlinesSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2026 | globenewswire.comSolid Biosciences: A Funded Challenge To Duchenne Gene Therapy's LimitationsSeptember 25, 2026 | seekingalpha.comA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names distributes income every single Thursday, with payouts reported as high as $1,051 a month. Chief Income Strategist Tim Plaehn breaks down the fund's real Thursday distribution history, how the income is generated, and how to buy it in any brokerage account.October 6 at 1:00 AM | Investors Alley (Ad)RBC Capital initiates coverage of Solid Biosciences at outperformSeptember 17, 2026 | msn.comSolid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC SaysSeptember 16, 2026 | finance.yahoo.comSolid Biosciences wins new Outperform at RBC on DMD opportunitySeptember 16, 2026 | seekingalpha.comSee More Solid Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Solid Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Solid Biosciences and other key companies, straight to your email. Email Address About Solid BiosciencesSolid Biosciences (NASDAQ:SLDB) is a biotechnology company focused on developing genetic medicines for patients with rare diseases. The company’s research platform is centered on adeno-associated virus (AAV) gene therapy and other genetic medicine technologies intended to address the underlying causes of disease. Solid Biosciences’ lead program is SGT-003, an investigational gene therapy being developed for Duchenne muscular dystrophy, a severe inherited neuromuscular disorder. The company is also developing additional programs for rare cardiac and neuromuscular conditions, including SGT-501 for BAG3-associated dilated cardiomyopathy. These candidates remain in clinical or preclinical development, and the company does not have an approved commercial product. Founded in 2013, Solid Biosciences is headquartered in the United States and conducts research and clinical development activities through U.S.-based operations and collaborations. The company is led by Chief Executive Officer Bo Cumbo. Its programs are designed for patients with serious rare diseases in the United States and potentially other markets, subject to clinical and regulatory outcomes.View Solid Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
